PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27723266-12 2018 In addition, SB431542, 5z-7-oxozeaenol and U0126 attenuated the TGF-beta1-induced secretion of PAI-1 and suPAR. U 0126 43-48 transforming growth factor beta 1 Homo sapiens 64-73 28779848-12 2017 Similarly, U0126 also partly inhibited the TGF-beta1-induced COX-2 expression. U 0126 11-16 transforming growth factor beta 1 Homo sapiens 43-52 29261154-4 2017 RESULTS: Inhibition of ERK signaling with the MEK inhibitor U0126 blunted the ability of TGF-beta1 to induce migration in pancreatic cancer Panc1 cells. U 0126 60-65 transforming growth factor beta 1 Homo sapiens 89-98 29261154-6 2017 Basal and TGF-beta1-dependent ERK, but not SMAD activation, was blocked by U0126 in Panc1 and other cell types indicating that ERK activation is downstream or independent of SMAD signaling. U 0126 75-80 transforming growth factor beta 1 Homo sapiens 10-19 28492136-5 2017 Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation. U 0126 47-52 transforming growth factor beta 1 Homo sapiens 65-74 28959141-9 2017 h-TGF-beta1 stimulated Smad2/3 and ERK1/2 phosphorylation, and the MEK1/2 inhibitor U0126 attenuated TGF-beta1-induced KKU-M213 cell invasion and MMP-9 production but moderately enhanced the cytokine growth inhibitory activity. U 0126 84-89 transforming growth factor beta 1 Homo sapiens 101-110 28365272-6 2017 The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders. U 0126 119-124 transforming growth factor beta 1 Homo sapiens 156-163 28365272-6 2017 The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders. U 0126 119-124 transforming growth factor beta 1 Homo sapiens 306-313 28365272-7 2017 Pre-treatment with UO126 was effective at blocking the TGFbeta-induced EMT, as evidenced by a reduction of alpha-SMA expression and protein labeling, E-cadherin labeling at cell borders, and a reduction of cell loss, cell elongation and capsular wrinkling. U 0126 19-24 transforming growth factor beta 1 Homo sapiens 55-62 28365272-8 2017 Post-treatment with UO126 at 2 and 6 h after TGFbeta addition was also effective at blocking EMT while post-treatment with UO126 at 24 and 48 h was not sufficient in hampering TGFbeta-induced EMT. U 0126 20-25 transforming growth factor beta 1 Homo sapiens 45-52 25482449-5 2015 Furthermore, TMEPAI gene activation by EGF and TGF-beta signaling was reduced by the MEK inhibitor U0126. U 0126 99-104 transforming growth factor beta 1 Homo sapiens 47-55 27720345-6 2017 SB431542 and U0126 prevented the TGF-beta1-induced increase of collagen content and TIMP-1 production of dental pulp cells. U 0126 13-18 transforming growth factor beta 1 Homo sapiens 33-42 26637807-8 2016 TGF-beta1-induced MMP-9 expression was decreased by both a MEK inhibitor, UO126, and a smad3 inhibitor, SIS3. U 0126 74-79 transforming growth factor beta 1 Homo sapiens 0-9 25882870-19 2015 However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells. U 0126 57-62 transforming growth factor beta 1 Homo sapiens 135-144 26001858-10 2015 Pretreatment by U0126 and SB431542 effectively prevented the TGF-beta1-induced cell growth and collagen content in SCAPs. U 0126 16-21 transforming growth factor beta 1 Homo sapiens 61-70 26001858-12 2015 U0126 prevented 0.5 ng/mL TGF-beta1-induced ALP activity but showed little effect on 10 ng/mL TGF-beta1-induced decline of ALP in SCAPs. U 0126 0-5 transforming growth factor beta 1 Homo sapiens 26-35 25428269-7 2015 Further, inhibition of Smad2 signalling using an inhibitor of activin receptor-linked kinase 5 SB431542 reduced TGF-beta1-induced Nox4 expression, while inhibition of ERK1/2 with the inhibitor of mitogen-activated protein kinase kinase 1/2 U0126 decreased both basal and TGF-beta1-induced Nox4 expression. U 0126 240-245 transforming growth factor beta 1 Homo sapiens 112-121 25428269-9 2015 Finally, TGF-beta1 enhanced endothelial cell proliferation, which was reduced by U0126 but not by SB431542. U 0126 81-86 transforming growth factor beta 1 Homo sapiens 9-18 25446723-7 2015 In addition, we show that neurocan, aggrecan, and brevican levels are significantly reduced when TGFbeta is administered in the presence of either the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin, but not the MEK1/2 inhibitor U0126. U 0126 237-242 transforming growth factor beta 1 Homo sapiens 97-104 24203464-6 2014 Treatment with the MEK inhibitor U0126 followed by co-stimulation with EGF and TGF-beta1 prevented the upregulation of Snail protein, EMT and motility, without impairing Snail mRNA. U 0126 33-38 transforming growth factor beta 1 Homo sapiens 79-88 25127907-8 2014 U0126 partly reversed this inhibitory effect of TGF-beta1. U 0126 0-5 transforming growth factor beta 1 Homo sapiens 48-57 24610459-9 2014 Moreover, TGF-beta1/FGF2-mediated EMT of HERS cells was reversed by the MEK1/2 inhibitor U0126. U 0126 89-94 transforming growth factor beta 1 Homo sapiens 10-19 24378341-6 2014 In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, suppressed the osteogenic differentiation induced by TGF-beta alone. U 0126 85-90 transforming growth factor beta 1 Homo sapiens 145-153 24378341-7 2014 Moreover, U0126 completely suppressed the osteogenic differentiation synergistically induced by TGF-beta and PDGF, whereas the phosphoinositide-3-kinase (PI3K) inhibitor, LY294002, only partially suppressed this effect. U 0126 10-15 transforming growth factor beta 1 Homo sapiens 96-104 24113427-7 2014 Of these kinases, only the inhibition of ERK1/2 by U0126, which was a specific inhibitor of mitogen-activated protein kinase/ERK1/2, effectively blocked the TGF-beta1-induced expression of TIMP-1. U 0126 51-56 transforming growth factor beta 1 Homo sapiens 157-166 25700356-8 2014 Additionally, U0126, an ERK signaling inhibitor, exerted a reversible effect on TGF-beta1-induced EMT and inhibited FOXM1 expression. U 0126 14-19 transforming growth factor beta 1 Homo sapiens 80-89 24383372-8 2013 ROS generation in response to TGF-beta1, measured as 2,7-dichlorofluorescein-diacetate fluorescence, was inhibited significantly by SB203580 and U0126, implicating both the p38 MAPK and Mekl/2/Erk1/2 signaling pathways. U 0126 145-150 transforming growth factor beta 1 Homo sapiens 30-39 22936401-8 2012 Treatment with SB203580 and U0126 reduced PLpro-induced expression of TGF-beta1, vimentin, and type I collagen. U 0126 28-33 transforming growth factor beta 1 Homo sapiens 70-79 22823995-13 2012 Interestingly, preincubation with mitogen-activated protein kinase (MAPK) cascade inhibitors U0126 (ERK pathway) and SB203580 (p38 pathway) decreased DIO3 mRNA levels and blocked the TGFbeta1-induced increase in DIO3 transcripts, suggesting that D3 induction might be mediated through the MAPK signaling pathway. U 0126 93-98 transforming growth factor beta 1 Homo sapiens 183-191 21713404-6 2012 In addition, EMT was reversed by PI3K inhibitor LY294002 and MEK1/2 inhibitor U0126, which suggested that A549 cells under stimulation of TGF-beta1 undergo a switch into mesenchymal cells and PI3K/Akt and MAPK/Erk1/2 signaling pathways serve to regulate TGF-beta1-induced EMT of A549 cells. U 0126 78-83 transforming growth factor beta 1 Homo sapiens 138-147 22441145-3 2012 The effect of Ras/MEK/ERK pathway on TGF-beta-mediated Lefty up-regulation was tested by adding K-ras small interfering RNA, MEK inhibitor U0126, or extracellular signal-regulated kinase (ERK) inhibitor LY294002. U 0126 139-144 transforming growth factor beta 1 Homo sapiens 37-45 21880834-8 2011 Addition of the ERK1/2 signaling inhibitor U0126 was able to prevent the TGF-beta(1)-mediated increase in TER and claudin expression. U 0126 43-48 transforming growth factor beta 1 Homo sapiens 73-83 21718706-13 2011 Selective p44/42 kinase inhibitor UO126 successfully inhibited TGF-beta(1) production. U 0126 34-39 transforming growth factor beta 1 Homo sapiens 63-74 22037456-7 2011 TGF-beta-induced aberrant expression of class III beta-tubulin was significantly reduced by pretreatment with U0126, an inhibitor of ERK phosphorylation. U 0126 110-115 transforming growth factor beta 1 Homo sapiens 0-8 21131601-7 2011 In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling. U 0126 130-135 transforming growth factor beta 1 Homo sapiens 23-31 21282571-6 2011 The contribution of non-Smad signaling pathways to TGF-beta-induced alpha-SMA and PAI-1 expression was assessed using the small molecule inhibitors U0126 and LY294002. U 0126 148-153 transforming growth factor beta 1 Homo sapiens 51-59 21282571-9 2011 The MEK-inhibitor U0126 blocked TGF-beta-induced PAI-1 expression, whereas alpha-SMA expression was enhanced. U 0126 18-23 transforming growth factor beta 1 Homo sapiens 32-40 21131601-7 2011 In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling. U 0126 130-135 transforming growth factor beta 1 Homo sapiens 194-202 20553909-5 2010 However, TSA inhibited the TGF-beta1-induced phosphorylation of extracellular signal regulated kinase (ERK), and the MAPK/ERK kinase inhibitor U0126, which specifically inhibits ERK, also prevented TGF-beta1-induced apoptosis. U 0126 143-148 transforming growth factor beta 1 Homo sapiens 198-207 20962016-7 2010 HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity. U 0126 112-117 transforming growth factor beta 1 Homo sapiens 36-45 20962016-7 2010 HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity. U 0126 112-117 transforming growth factor beta 1 Homo sapiens 155-164 18655827-8 2008 Furthermore, a MEK-specific inhibitor (U0126) abrogated BK-induced TGF-beta1 secretion, Smad2 phosphorylation, and alpha-SMA expression. U 0126 39-44 transforming growth factor beta 1 Homo sapiens 67-76 18023419-10 2008 Additionally, U0126, a specific inhibitor of ERK1/2, also significantly attenuated the TGF-beta1-stimulated VEGF synthesis. U 0126 14-19 transforming growth factor beta 1 Homo sapiens 87-96 18218921-6 2008 This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta1 signaling. U 0126 195-200 transforming growth factor beta 1 Homo sapiens 270-279 18571460-4 2008 Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway. U 0126 158-163 transforming growth factor beta 1 Homo sapiens 32-41 18571460-4 2008 Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway. U 0126 158-163 transforming growth factor beta 1 Homo sapiens 246-255 17409139-6 2007 Specific MEK1/2 inhibitors, flavenoid PD98059 and U0126, decreased the basal and TGF-beta1-stimulated Vp-1 expression by 95% or more. U 0126 50-55 transforming growth factor beta 1 Homo sapiens 81-90 17096210-8 2007 Pretreatment with U0126, an inhibitor of ERK1/2, significantly enhanced the TGF-beta1-mediated antiproliferative and apoptosis induction effects in BEP2D cells. U 0126 18-23 transforming growth factor beta 1 Homo sapiens 76-85 17209135-4 2007 The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126. U 0126 306-311 transforming growth factor beta 1 Homo sapiens 54-62 17313766-5 2006 RESULTS: (1) the production in 15 and 25 micromol/L U0126 incubated groups was (87 +/- 11) pg/ml and (75 +/- 19) pg/ml respectively, which was significantly decreased compared with that in 10(-7) mol/L ALDO incubated group (P < 0.05), however, the amount of TGF-beta1 in these groups were still significant higher than that in the control group (P < 0.05). U 0126 52-57 transforming growth factor beta 1 Homo sapiens 261-270 15537865-7 2005 Finally, inhibition of MAP kinase signaling, using the selective inhibitor U0126, promoted FSH-R expression and further enhanced TGF beta1-induced FSH-R expression in vitro. U 0126 75-80 transforming growth factor beta 1 Homo sapiens 129-138 16139919-4 2005 RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K. U 0126 120-125 transforming growth factor beta 1 Homo sapiens 141-150 16141544-5 2005 ERK inhibitor, U0126 completely prevented TGF-beta production. U 0126 15-20 transforming growth factor beta 1 Homo sapiens 42-50 15963850-6 2005 The farnesyl transferase inhibitor L744832 and the MEK inhibitor U0126 both restored p27 levels and cell-cycle arrest in response to TGF-beta. U 0126 65-70 transforming growth factor beta 1 Homo sapiens 133-141 16123076-6 2005 The effect of TGF-beta and GnRHa on FMOD expression was reversed following pretreatment of LSMC and MSMC with Smad3 SiRNA and U0126 (MEK1/2 inhibitor), respectively. U 0126 126-131 transforming growth factor beta 1 Homo sapiens 14-22 15956343-16 2005 However, TGF-beta even in MCC-DNTbetaRII cells induced ERK1/2 phosphorylation, and treatment with MEK inhibitor, UO126, inhibited the antagonistic effects of TGF-beta on IGFBP-3. U 0126 113-118 transforming growth factor beta 1 Homo sapiens 158-166 15956343-17 2005 Furthermore, UO126 blocked the TGF-beta inhibition of STAT-1 phosphorylation induced by IGFBP-3. U 0126 13-18 transforming growth factor beta 1 Homo sapiens 31-39 15468069-5 2005 Inhibitors of this pathway, PD98059 and U0126, downregulated TGF-beta-induced expression of TIMP-3 RNA and protein. U 0126 40-45 transforming growth factor beta 1 Homo sapiens 61-69 15265761-8 2004 Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression. U 0126 18-24 transforming growth factor beta 1 Homo sapiens 83-92 15192088-10 2004 When an inhibitor of MAPK (U0126) was used, the TGF-beta-mediated proliferative response in HeLa cells was completely abolished. U 0126 27-32 transforming growth factor beta 1 Homo sapiens 48-56 15531510-4 2004 GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun. U 0126 207-212 transforming growth factor beta 1 Homo sapiens 10-18 15531510-4 2004 GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun. U 0126 207-212 transforming growth factor beta 1 Homo sapiens 278-286 15044465-7 2004 TGF-beta-induced motility was blocked by coincubation with either the phosphatidylinositol 3-kinase inhibitor LY294002, the mitogen-activated protein kinase (MAPK) inhibitor U0126, the p38 MAPK inhibitor SB202190, and an integrin beta(1) blocking antibody. U 0126 174-179 transforming growth factor beta 1 Homo sapiens 0-8 14726474-8 2004 Lastly, BNP stimulated the extracellular signal-related kinase pathway via cyclic guanosine monophosphate-dependent protein kinase signaling, and two mitogen-activated protein kinase kinase inhibitors, U0126 and PD98059, reversed BNP inhibition of TGF-beta-induced collagen-1 expression. U 0126 202-207 transforming growth factor beta 1 Homo sapiens 248-256 14751283-7 2004 TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1. U 0126 73-78 transforming growth factor beta 1 Homo sapiens 0-9 14751283-7 2004 TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1. U 0126 73-78 transforming growth factor beta 1 Homo sapiens 276-285 14751283-10 2004 Of note, wortmannin and U0126, as well as kappabeta-decoy DNA, abolished the anti-apoptotic effect of TGF-beta1, corroborating the notion that both PI3k/Akt and MAPK/Erk1,2 pathways, and NF-kappabeta activity are necessary for the anti-apoptotic activity of TGF-beta1. U 0126 24-29 transforming growth factor beta 1 Homo sapiens 102-111 12441075-6 2002 U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells. U 0126 0-5 transforming growth factor beta 1 Homo sapiens 47-57 14566975-8 2003 VEGF mRNA levels and protein secretion induced by TGF-beta were significantly inhibited by SB203580 and U0126, inhibitors of MAP kinases, but not by staurosporine and PDTC, protein kinase C and NF-kappaB pathway inhibitors, respectively. U 0126 104-109 transforming growth factor beta 1 Homo sapiens 50-58 12717386-7 2003 The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities. U 0126 92-97 transforming growth factor beta 1 Homo sapiens 128-136 11741826-3 2002 ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment. U 0126 207-213 transforming growth factor beta 1 Homo sapiens 415-424 11978861-6 2002 TGF-beta1-treated sensory neurons showed a significant reduction in the number of these puncta, an effect that was blocked by the MAP/ERK kinase inhibitor U0126. U 0126 155-160 transforming growth factor beta 1 Homo sapiens 0-9 11500937-5 2001 We confirmed that PD98059 or U0126 did actually suppress the phosphorylation of p42/p44 MAP kinase by TGF-beta in our preparations. U 0126 29-34 transforming growth factor beta 1 Homo sapiens 102-110 31955434-9 2020 U0126 attenuated the TGF-beta1-induced expression/secretion of uPAR, but not PAI-1 in SCAP. U 0126 0-5 transforming growth factor beta 1 Homo sapiens 21-30 34003249-7 2021 SGLT2 and ERK inhibition on D-glucose, 25mM, and TGF-beta1, 0.75ng/ml, treated cells was explored using dapagliflozin and U0126, respectively. U 0126 122-127 transforming growth factor beta 1 Homo sapiens 49-58 33148869-11 2020 However, 5Z-7-oxozeaenol, SB203580 and U0126 only reversed the stimulatory effect of TGF-beta1 on ALP. U 0126 39-44 transforming growth factor beta 1 Homo sapiens 85-94 33025417-11 2022 Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis. U 0126 30-35 transforming growth factor beta 1 Homo sapiens 118-123 31807174-8 2019 Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells. U 0126 110-115 transforming growth factor beta 1 Homo sapiens 231-240 31666990-9 2019 The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling. U 0126 104-109 transforming growth factor beta 1 Homo sapiens 4-13 30483803-3 2019 It was demonstrated that U0126 significantly inhibited the proliferation, migration and collagen contraction of HTFs stimulated with TGF-beta1. U 0126 25-30 transforming growth factor beta 1 Homo sapiens 133-142 30908581-7 2019 PI3K/AKT inhibitor (wortmannin) and MEK/ERK inhibitor (U0126) reduced the TGF-beta1-induced synthesis of FN, COL3, and alpha-SMA in HPFs. U 0126 55-60 transforming growth factor beta 1 Homo sapiens 74-83 30483803-4 2019 In addition, U0126 largely attenuated the TGF-beta1-induced conversion of HTFs into myofibroblasts, as indicated by a downregulation of the mRNA and protein expression of alpha-smooth muscle actin and zinc finger protein SNAI1, and by ameliorating the 3D-collagen contraction response. U 0126 13-18 transforming growth factor beta 1 Homo sapiens 42-51 30483803-5 2019 Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1. U 0126 17-22 transforming growth factor beta 1 Homo sapiens 38-47 30483803-5 2019 Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1. U 0126 17-22 transforming growth factor beta 1 Homo sapiens 318-327 30483803-5 2019 Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1. U 0126 223-228 transforming growth factor beta 1 Homo sapiens 38-47 30483803-5 2019 Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1. U 0126 223-228 transforming growth factor beta 1 Homo sapiens 318-327 30059670-11 2018 SIS3, U0126 and SB203580 all partly attenuated alpha-SMA mRNA expression under TGF-beta1 treatment. U 0126 6-11 transforming growth factor beta 1 Homo sapiens 79-88